# HCRN GU16-260 (NCT03117309)

> Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03117309
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Michael B. Atkins, MD
- Conditions: Advanced Renal Cell Carcinoma
- Interventions: Nivolumab 240 mg; Ipilimumab 1mg/kg; Nivolumab 3mg/kg; Nivolumab 360mg
- Enrollment: 164
- Primary outcome: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients

## Indexed commentary on HCRN GU16-260 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 13
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=hcrn-gu16-260-nct03117309

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03117309", "email": "<work email>"}; the inbox owner confirms by the emailed link.